Cell scaffold constructs

• US 9,271,824 B2
• Filed: 11/20/2012
• Issued: 03/01/2016
• Est. Priority Date: 11/04/2008
• Status: Expired due to Fees

• Current Assignee: Orgagen, Inc.
• Original Assignee: RegenMedTX, LLC
• Inventors: Ludlow, John W., Jayo, Manuel J., Basu, Joydeep, Bertram, Timothy A., Genheimer, Christopher W., Guthrie, Kelly I., Ilagan, Roger M., Jain, Deepak, Knight, Oluwatoyin A., Payne, Richard, Quinlan, Sarah F., Rapoport, H. Scott, Sangha, Namrata D.
• Primary Examiner(s): GHERBI, SUZETTE JAIME J
• Application Number:
  US13/682,614
• Publication Number:
  US 20130173015A1
• Time in Patent Office: 1,197 Days
• Field of Search: 623 2364- 237
• US Class Current: 1/1
• CPC Class Codes: A61F 2/042 Urinary bladders
• CPC Class Codes: A61L 2430/22 for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3826 Muscle cells, e.g. smooth muscle cells
• CPC Class Codes: A61L 27/3882 Hollow organs, e.g. bladder, esophagus, urether, uterus
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

The present invention relates to the regeneration, reconstruction, repair, augmentation or replacement of organs or tissue structures using scaffolds and autologous cells that are not derived from such organs or tissues.

Claims

1. An implantable construct for replacement of a defective bladder in a human subject comprising

a) a tubular scaffold having a first open end configured for anastomosis to an opening in the subject'"'"'s abdominal wall, a second open end configured to connect to a ureter;

and

b) an autologous cell population that is not derived from the defective bladder, deposited on or in a surface of the tubular scaffold,

wherein the cell population is a smooth muscle cell population derived from adipose tissue or peripheral blood, and wherein the implantable construct is adapted for temporary storage and passage of urine.

2. The implantable construct of claim 1, wherein the first open end is configured to connect to an abdominal wall section.

3. The implantable construct of claim 1, wherein the first open end is configured to form a stoma.

4. The implantable construct of claim 1, wherein the first open end is configured to be positioned flush with the abdominal wall.

5. The implantable construct of claim 1, wherein the first open end is configured to be sutured to the skin of the subject.

6. The implantable construct of claim 1, wherein the first open end is configured to be anastomosed to the skin.

7. The implantable construct of claim 3, wherein the stoma further comprises a stoma button.

8. The implantable construct of claim 1, wherein the tubular scaffold further comprises a side opening configured to connect to a second ureter.

9. The implantable construct of claim 1, wherein the biocompatible scaffold is biodegradable.

10. The implantable construct of claim 1, wherein the scaffold comprises a material selected from the group consisting of polyglycolic acid, polylactic acid, and a copolymer of polyglycolic acid and polylactic acid.

11. The implantable construct of claim 1, wherein the diversion is free of urothelial cells.

12. The implantable construct of claim 1, wherein the smooth muscle cell (SMC) population is not derived from in vitro differentiation of mesenchymal stem cells (MSCs).

13. The implantable construct of claim 1, wherein the tubular scaffold is coated with a biocompatible and biodegradable shape-setting material.

14. The implantable construct of claim 13, wherein the shape-setting material comprises a poly-lactide-co-glycolide copolymer.